Case Report Etanercept-Induced Pityriasis Lichenoides Chronica in a Patient with Rheumatoid Arthritis Andrés F. Echeverri, 1 Andrés Vidal, 2 Carlos A. Cañas, 1 Andrés Agualimpia, 1 Gabriel J. Tobón, 1 and Fabio Bonilla-Abadía 1 1 Rheumatology Unit, Fundaci´ on Valle del Lili, Carrera 98 N. 18-49, Cali, Colombia 2 Dermatology Unit, Fundaci´ on Valle del Lili, Carrera 98 N. 18-49, Cali, Colombia Correspondence should be addressed to Andr´ es F. Echeverri; afeg79@hotmail.com Received 22 September 2014; Revised 10 December 2014; Accepted 9 February 2015 Academic Editor: Enno Schmidt Copyright © 2015 Andr´ es F. Echeverri et al. Tis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. We present a 74-year-old female patient who developed a pityriasis lichenoides chronica (PLC) during etanercept therapy. Tis association is not described in the literature and might be considered in the spectrum of cutaneous adverse reactions of etanercept. 1. Introduction Pityriasis lichenoides chronica (PLC) is a rare infammatory skin disorder of unknown etiology that is considered as a subtype of pityriasis lichenoides. Patients with PLC usually present with widely distributed red-brown papules on the trunk and extremities. Te diagnosis of PLC is based upon the fndings on the physical examination and a skin biopsy is required to confrm the diagnosis [1]. Several case reports have shown the association of PLC in patients with infam- matory diseases treated with antitumor necrosis factor alpha (anti-TNF) therapies. [2–4]. To our knowledge this is the frst case reported in the literature of PLC associated with etanercept treatment. 2. Case Report A 74-year-old female patient with seropositive rheumatoid arthritis (RA) diagnosed 18 years ago, with involvement in proximal interphalangeal joints, metacarpophalangeal, wrists, elbows, ankles, and lef knee, was treated with chloroquine, prednisolone, and methotrexate for several years showing remission of the disease. In recent years, she presented an infammatory fare with reappearance of articular infammatory signs, elevated acute phase reactants, and functional limitation. For this reason lefunomide was added to treatment without clinical efcacy. Tus, biological treatment with etanercept 50 mg subcutaneous every week was started with improvement of infammatory signs and symptoms. Afer six weeks of etanercept onset, she was evaluated by Rheumatology and Dermatology services for the appearance of erythematosus and desquamative papules, with central scaling on the back and arms (Figure 1). She had no personal or family history of psoriasis or other skin diseases. A skin biopsy was indicated. Histological description showed parakeratosis and mild acanthosis in the epidermis layer, and perivascular lym- phocytic infltrates in the papillary dermis, extravasation of red blood cells, and basal layer vacuolar change were also observed. Histological fndings were consistent with PLC (Figure 2). Autoimmunity tests revealed a positive rheumatoid factor in 148 UI/ml (<14 UI/ml) and the antinuclear antibodies (ANAs) were negative. Treatment with daily topical corticosteroids was initiated. Afer one month of treatment, the rash has decreased and treatment with etanercept was continued. 3. Discussion Te tumor necrosis factor alpha (TNF-) antagonists are widely used for the treatment of chronic infammatory disorders including RA. Te cutaneous adverse reactions are an important component described in this therapeutic group Hindawi Publishing Corporation Case Reports in Dermatological Medicine Volume 2015, Article ID 168063, 2 pages http://dx.doi.org/10.1155/2015/168063